Global Women's Health Academy

Recent Updates on the Role of Noninvasive Prenatal Screening in Optimizing Fetal Outcomes

Each year in the United States approximately 2 million pregnancies are lost, of which about 600,000 are due to miscarriage. Chromosomal abnormaliti...

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Each year in the United States approximately 2 million pregnancies are lost, of which about 600,000 are due to miscarriage. Chromosomal abnormalities are common causes of congenital malformation and miscarriages, with nearly half of all miscarriages associated with abnormal karyotypes that occur during the first few weeks of life. Screening for fetal chromosomal abnormalities has for many years been identified as an important component of obstetrical care by ACOG. In 2012, ACOG released a revised set of guidelines on this topic which recommends that fetal chromosomal testing be offered to all pregnant women, regardless of age. The basis for this revision was the improvements in low-risk, non-invasive screening methods. 

    Join us as Dr. Martin Chavez and Dr. Ronald Wapner discuss how to integrate the fetal chromosomal aneuploidy screening guidelines into prenatal visits for all pregnant patients, as well as the benefits and disadvantages of the various traditional approaches and the evolving, non-invasive fetal chromosomal aneuploidy screening tests that are available.

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Martin R. Chavez, MD, FACOG
    Director of Maternal Fetal Medicine
    Winthrop University Hospital
    Clinical Associate Professor of Obstetrics, Gynecology and Reproductive Medicine
    Stony Brook University School of Medicine
    Mineola, NY

    Dr. Chavez receives consulting fees and is a speaker for Illumina Inc. and Progenity Inc.

    Ronald J. Wapner, MD
    Vice Chair of Research
    Director of Reproductive Genetics
    Columbia University Medical Center
    New York, NY

    Dr. Wapner has contracted research with Illumina Inc. and Natera.

    Moderator:
    Matt Birnholz, MD
    Medical Director
    ReachMD
    Chicago, IL

    Matt Birnholz, MD has nothing to disclose.   

    The following reviewers/planners/authors have reported real or apparent conflicts of interest that have been resolved:

    • Sean T. Barrett, CHCP has nothing to disclose
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Robert Schneider has nothing to disclose.
    • Jennifer Spear Smith, PhD has nothing to disclose.
    • Elizabeth Stephens has nothing to disclose.
  • Target Audience

    This activity is designed to meet the educational needs of Maternal Fetal Medicine Specialists, Obstetricians and Gynecologists, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, and Genetic Counselors.

  • Learning Objectives

    At the conclusion of this activity, participants will be better able to:

    • Explain the advantages  and disadvantages of traditional fetal chromosomal screening tests compared with the evolving, noninvasive screening tests
    • Incorporate evidenced-and guideline-based  screening and diagnostic protocols into clinical decision-making when assessing fetal chromosomal aneuploidies
    • Explain the evolving role of NIPT in a general obstetrical population
    • Describe the concept of “positive predictive value” and how it is applied to the results obtained with NIPT
    • Identify the evolving role of NIPT in evaluating microdeletions
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Illumina Inc.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required
Optional